検索 条件検索
wx_img
Inquiry Form
  1. Home
  2. Tucatinib

Tucatinib

In August 2023, phase III results for tyrosine kinase inhibitor Tukysa (tucatinib), in combination with antibody-drug conjugate Kadcyla (ado-trastuzumab emtansine), which met its primary endpoint of progression-free survival in HER-2 breast cancer patients.
TUKYSA (tucatinib) is an oral medicine that is a tyrosine kinase inhibitor of the HER2 protein. It is approved in more than 40 countries.

5-Nitroanthranilonitrile
5-Nitroanthranilonitrile
CM243521
17420-30-3
N'-(2-cyano-4-nitrophenyl)-N,N-dimethylmethanimidamide
N
CM1018960
1203904-18-0
N'-(4-amino-2-cyanophenyl)-N,N-dimethylmethanimidamide
N
CM1018901
2131230-48-1
(E)-N'-(2-cyano-4-(3-(1-hydroxy-2-methylpropan-2-yl)thioureido)phenyl)-N,N-dimethylformimidamide
(E)-N
CM329512
1429755-57-6
4-(2-Methyl-4-nitrophenoxy)pyridin-2-amine
4-(2-Methyl-4-nitrophenoxy)pyridin-2-amine
CM323769
864244-98-4
7-(2-methyl-4-nitrophenoxy)-[1,2,4]triazolo[1,5-a]pyridine
7-(2-methyl-4-nitrophenoxy)-[1,2,4]triazolo[1,5-a]pyridine
CM1019389
937263-44-0
4-([1,2,4]Triazolo[1,5-a]pyridin-7-yloxy)-3-methylaniline
4-([1,2,4]Triazolo[1,5-a]pyridin-7-yloxy)-3-methylaniline
CM322205
937263-71-3